A new grant from the Georgia Research Alliance (GRA) is backing an ambitious effort by Georgia Tech scientists to accelerate the development of human antibody therapies — a class of medicines that has transformed treatment across cancer, autoimmune disease, and infectious illness, yet it cannot be generated against many disease targets.

The $250,000 funding award, made through GRA’s Innovation and Entrepreneurship (I&E) program, supports the translational work of Ankur Singh, Professor in the George W. Woodruff School of Mechanical Engineering and the Wallace H. Coulter Department of Biomedical Engineering, and Andrés García, Regents’ Professor in Mechanical Engineering and the Executive Director of the Parker H. Petit Institute for Bioengineering and Bioscience. Singh and García are collaborating to develop functional human antibodies against some of the most difficult-to-treat diseases. While antibody therapies already benefit an estimated 20 million patients worldwide, fewer than 10 percent of discovery efforts ultimately yield candidates suitable for clinical use.

This shortfall spans major disease areas — from oncology and autoimmune disorders to heart and metabolism-related conditions and neurological and infectious diseases — limiting therapeutic options for patients. The challenge lies not only in identifying candidate antibodies, but in engineering them to function reliably in the human body.

“The I&E program exists to bridge the gap between a discovery that works in the lab and one that can anchor a company,” said Justin Burns, Chief Innovation Officer and Vice President for Innovation and Entrepreneurship at GRA. “Singh and García are tackling a problem the field has faced for decades: A significant fraction of drug targets remains inaccessible to antibody-based therapies. Our goal is to help move bold, high-potential science toward real-world impact.”

GRA’s model targets a well-known bottleneck in translation. While university labs generate promising technologies, many stall before reaching the marketplace due to a lack of validation and early-stage development. 

Singh and García aim to overcome this barrier by using a proprietary antibody-engineering framework developed in Singh’s laboratory, and supported by an earlier GRA grant. The objective is straightforward: Increase the success rate of discovery efforts so more antibody candidates can advance toward clinical use.

“The implications extend well beyond our laboratory,” said Singh. “By expanding the pipeline of functional human antibodies, we can begin to address diseases that currently lack durable treatment options. GRA’s support is transformative — not only for advancing the science, but for positioning Georgia as a leader in biotechnology innovation.”

The project is built with real-world use in mind, aiming to turn the research into a new company and eventually a clinical product. By testing the idea early and lowering risk, the team hopes to attract investment and move the technology quickly beyond the Institute. 

García emphasized the translational vision of the work. 

“This is a transformative platform technology that overcomes major bottlenecks in antibody discovery and will accelerate and increase the efficiency of this powerful class of therapeutics,” he said.

“This effort is about rethinking how we design antibodies from the ground up — integrating biological insight with engineering principles to produce molecules that are not just viable, but clinically meaningful,” he said. “With GRA’s support, we can de-risk early discovery and create a clearer path from promising concepts to therapies that reach patients.”

 Tracey Mullen, a seasoned biopharma executive, entrepreneur, and antibody discovery and engineering leader currently serving as Chief Strategy Officer at Mosaic Biosciences, is advising the team on translational strategy, commercial development, and company formation. 

“The ability to rapidly generate functional human antibodies in physiologically relevant systems could meaningfully change how therapeutic discovery is approached,” Mullen said. “By moving beyond largely empirical, animal- or screening-heavy workflows and incorporating human-specific, mechanism-informed evaluation earlier in the process, this platform has the potential to generate more relevant antibody candidates and create a stronger path from discovery concept to translational development.”

As global demand for advanced therapeutics grows, efforts like this reflect a broader shift in how innovation moves from bench to bedside — one driven not only by scientific ingenuity, but by targeted investment at critical early stages.